You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
AmoyDx and Premia will provide large-scale cancer patient screening in Asia to support Loxo-292 RET inhibitor clinical development.
The overlapping development programs for first-generation larotrectinib and second-generation LOXO-195 signal narrowing drug development timelines in the era of precision oncology.
In order to be eligible for the drug, patients must have NTRK fusions, which may be determined via various tests including NGS and FISH.
Veracyte will use its Afirma assay to analyze thyroid cancers and inform Loxo's drug development pipeline for targeted therapies.
The companies will develop a version of Illumina's TruSight 170 sequencing panel for two of Loxo's targeted oncology drugs.
Data presented at ASCO showing 76 percent of cancer patients responded to larotrectinib could lead to the availability of the first tissue-agnostic targeted drug.
The companies are aiming to develop and commercialize a test to identify patients likely to respond to Loxo's cancer drug larotrectinib.
The company is recruiting patients with TRK fusions and different cancer types in a Phase II basket trial that may pave the way for a "molecular label" for its drug.
UK Royal Statistical Society is organizing a working group to develop guidelines for assessing COVID-19 tests, the Guardian reports.
The Washington Post reports that the White House chief of staff has asked the US Food and Drug Administration to justify the stricter standards it is seeking for a coronavirus vaccine.
President Donald Trump's "good genes" comment raises eugenics concerns, CNN reports.
In PLOS this week: genetic analysis of tremor condition, analysis of a West and Central African tree used in traditional medicine, and more.